AI Terminal
DIACEUTICS PLC
AGM Information • May 19, 2021
7596_dva_2021-05-19_156d4351-0220-4415-84bd-bc6fbbb1ae9b.html
AGM Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1882Z
Diaceutics PLC
19 May 2021
19 May 2021
Diaceutics PLC
("Diaceutics" or the "Company")
Results of Annual General Meeting
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed by way of a poll.
The proxy votes received from shareholders in respect of each resolution are set out below and are available on the Company's website www.diaceutics.com
| Resolution | For | Against | Total votes cast | Withheld | |||
| Number of votes | % | Number of votes | % | Number of votes | |||
| 1 | Ordinary resolution to receive and consider the 2020 Financial Statements | 60,078,658 | 100.00% | 0 | 0.00% | 60,078,658 | 4,000 |
| 2 | Ordinary resolution to approve the directors' remuneration report | 59,349,644 | 98.79% | 729,014 | 1.21% | 60,078,658 | 4,000 |
| 3 | Ordinary resolution to re-elect Deborah Davis as a director | 60,078,658 | 100.00% | 0 | 0.00% | 60,078,658 | 4,000 |
| 4 | Ordinary resolution to re-elect Ryan Keeling as a director | 59,111,939 | 98.39% | 966,719 | 1.61% | 60,078,658 | 4,000 |
| 5 | Ordinary resolution to re-appoint PricewaterhouseCoopers LLP as auditors | 59,719,155 | 98.40% | 359,503 | 0.60% | 60,078,678 | 4,000 |
| 6 | Ordinary resolution to authorise the directors to determine the remuneration of the auditors | 59,722,240 | 98.41% | 356,418 | 0.59% | 60,078,658 | 4,000 |
| 7 | Ordinary resolution to authorise the directors to allot shares | 60,077,658 | 99.99% | 1,000 | 0.01% | 60,078,658 | 4,000 |
| 8 | Special resolution to authorise the directors to disapply pre-emption rights | 60,068,223 | 99.98% | 10,435 | 0.02% | 60,078,658 | 4,000 |
| 9 | Special resolution to authorise the directors to purchase own shares | 58,032,658 | 99.99% | 7,000 | 0.01% | 58,039,658 | 2,043,000 |
Enquiries:
| Diaceutics PLC Peter Keeling, Chief Executive Officer Philip White, Chief Financial Officer |
www.diaceutics.com via Alma PR |
| Cenkos Securities plc (Nominated adviser and broker) Callum Davidson / Giles Balleny Michael Johnson (Sales) |
+44 (0)207 397 8900 |
| Alma PR Caroline Forde Robyn Fisher Kieran Breheny |
Tel: +44 (0)20 3405 0205 [email protected] |
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries. www.diaceutics.com
About DXRX - The Diagnostic Network®
DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGZZGMKDLGGMZM